Search
Filter Results
Displaying 101–110 of 155 for “Visions 2020”
-
Mar 3, 2022
Clearside Biomedical Appoints Benjamin R. Yerxa, Ph.D. to its Board of Directors
In the PressIndustry Veteran Brings Broad Ophthalmology Research & Development Expertise.
-
Feb 28, 2022
Beacon StoriesFoundation Arizona chapter president Fai Mo is sharing, in his own words, his experiences with being diagnosed with retinitis pigmentosa and how he found comfort in the Foundation Fighting Blindness community.
-
Feb 24, 2022
Second Sight Agrees to Merger to Maintain Retinal and Cortical Prostheses Programs
Research NewsCompany has been unable to meet revenue goals for the Argus II®
-
Oct 8, 2021
Foundation Hosts Workshop on USH1B Research and Therapy Development
Research NewsEmerging dual-vector gene therapies to address current cargo-size limitations were highlighted during the meeting.
-
Oct 7, 2021
Covid Revealed What Science Can Do When Funding is Found
In the Press‘In some ways, the pandemic ought to make us all feel more upbeat about the long-term future of medical research.’
-
Funded Foundation Fighting Blindness Grants and Awards for Fiscal Year 2021 (July 1, 2020–June 30, 2021)
-
Sep 27, 2021
Foundation Awarded 21 New Grants in FY2021 Totaling More than $14.2 Million
Research NewsCurrent research portfolio is comprised of nearly 100 projects at prominent institutions around the world
-
May 24, 2021
Investigators Report Partial Vision Restoration for One Patient in Optogenetic Therapy Trial
Research NewsThe gene-agnostic approach is designed to restore some vision to people with advanced vision loss
-
May 20, 2021
Foundation NewsThe free webinar for eye care professionals, on June 21, will feature some of the intriguing and innovative research efforts underway for inherited retinal diseases and AMD.
An overview of the Foundation’s no-cost genetic testing program will also be presented.
-
May 18, 2021
In the PressUses novel, mutation agnostic optogenetics approach to restore vision in underserved forms of blindness. Company backed by leading life science investors including Octagon Capital, Samsara BioCapital and Casdin Capital, along with founding investors Atlas Venture, Mission BioCapital and Foundation Fighting Blindness.